Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592867 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL19385435 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11694103 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4514648 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4517239 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1784070 | 1.00 | — | — | |
| SCHEMBL335804 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL8139520 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL597810 | 1.00 | — | — | |
| SCHEMBL842302 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048185-A1 | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1952814-A1 | THERAPEUTIC AGENT COMPRISING GLYCOLIPID DERIVATIVE CAPABLE OF INHIBITING THE FUNCTION OF NKT CELL AS ACTIVE INGREDIENT | Japan as represented by President of National Center of Neurology and Psychiatry (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048185-A1 | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient | CD4, NFATC1, NR1H2 | TSHR 3544/4885THRB 3117/4885DNM1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.